Incidence of EGFR, kras, BRAF, ALK, and p53 alterations in a cohort of 218 consecutively tested patients from a certified lung cancer center: Correlation with clinical characteristics and treatment outcome

被引：1
|
作者：
Lueers, Anne Christina
Halbfass, Volker
Frenzel, Regina
Scriba, Douglas
Willborn, Kay
Falk, Markus
Hellas, Cora
Tiemann, Markus
Griesinger, Frank
机构：
[1] Pius Hosp Oldenburg, Hematol & Oncol, Oldenburg, Germany
[2] Pius Hosp Oldenburg, Dept Pneumol, Oldenburg, Germany
[3] Pius Hosp Oldenburg, Dept Thorac Surg, Oldenburg, Germany
[4] Pius Hosp Oldenburg, Dept Radiotherapy, Oldenburg, Germany
[5] Hematopathol Hamburg, Hamburg, Germany
[6] Pius Hosp, Dept Med Oncol, Oldenburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19064
引用
收藏
页数：1
相关论文
共 6 条
  • [1] INCIDENCE OF EGFR, KRAS, BRAF, ALK, AND P53 ALTERATIONS IN A COHORT OF 159 CONSECUTIVELY TESTED PATIENTS FROM A CERTIFIED LUNG CANCER CENTER, CORRELATION WITH CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME
    Halbfass, Volker
    Prenzel, Regina
    Scriba, Douglas
    Willborn, Kay
    Falk, Markus
    Hallas, Cora
    Tiemann, Markus
    Griesinger, Frank
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S961 - S961
  • [2] Incidence of EGFR, KRAS, BRAF, ALK and P53 alterations in a cohort of 159 consecutively tested patients from 1 DKG certified lung cancer center and correlation with clinical characteristics
    Halbfass, V
    Prenzel, R.
    Scriba, D.
    Willborn, K. -C.
    Stropiep, U.
    Falk, M.
    Hallas, C.
    Griesinger, F.
    Tiemann, M.
    ONKOLOGIE, 2013, 36 : 251 - 251
  • [3] Incidence and treatment outcome of EGFR and inactivating P53 alterations in a cohort of 218 consecutively tested patients from a certified lung cancer center
    Lueers, A.
    Prenzel, R.
    Scriba, D.
    Willborn, K. -C
    Stropiep, U.
    Falk, M.
    Hallas, C.
    Tiemann, M.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 227 - 228
  • [4] Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
    Lai, E.
    Schirripa, M.
    Puzzoni, M.
    Loupakis, F.
    Ziranu, P.
    Pretta, A.
    Giampieri, R.
    Mariani, S.
    Liscia, N.
    Soro, P.
    Pusceddu, V.
    Astara, G.
    Impera, V.
    Camera, S.
    Musio, F.
    Zaniboni, A.
    Fassan, M.
    Lonardi, S.
    Zagonel, V.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients. Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
    Dugay, Frederic
    Llamas-Gutierrez, Francisco
    Gournay, Marjory
    Medane, Sarah
    Mazet, Francois
    Chiforeanu, Dan Christian
    Becker, Emmanuelle
    Lamy, Regine
    Lena, Herve
    Rioux-Leclercq, Nathalie
    Belaud-Rotureau, Marc-Antoine
    Cabillic, Florian
    ONCOTARGET, 2017, 8 (32) : 53336 - 53351
  • [6] VEGF165, Bcl-2, p53, COX-2 and HER-family expression in patients with stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) and correlation with clinical outcome.
    Timotheadou, E
    Murray, S
    Linardou, H
    Vrettou, AV
    Skrickova, J
    Kosmidis, P
    Skarlos, DV
    Pectasides, D
    Fountzilas, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 681S - 681S
1